Although ALK mutations have been observed in all clinical risk groups, a recent study analyzing a large cohort of more than 1500 NB patients demonstrated that the presence of an ALK mutation was independently correlated with survival: patients with an ALK mutation showed a 1.4-fold greater risk of an event within 5 years than patients without one. The gene discussed is ALK; the disease is neuroblastoma.